Serum exosomal miR-378 upregulation is associated with poor prognosis in non-small-cell lung cancer patients
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serum exosomal miR-378 upregulation is associated with poor prognosis in non-small-cell lung cancer patients
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL LABORATORY ANALYSIS
Volume -, Issue -, Pages e23237
Publisher
Wiley
Online
2020-02-15
DOI
10.1002/jcla.23237
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MiR-378 promotes the cell proliferation of osteosarcoma through down-regulating the expression of kruppel-like factor 9
- (2018) Ningning Peng et al. Biochemistry and Cell Biology
- MicroRNA-378 regulates epithelial-mesenchymal transition and metastasis of melanoma by inhibiting FOXN3 expression through the Wnt/β-catenin pathway
- (2018) Mengyao Sun et al. CELL BIOLOGY INTERNATIONAL
- MiR-378 and MiR-1827 Regulate Tumor Invasion, Migration and Angiogenesis in Human Lung Adenocarcinoma by Targeting RBX1 and CRKL, Respectively
- (2018) Chai San Ho et al. Journal of Cancer
- miR-378 serves as a prognostic biomarker in cholangiocarcinoma and promotes tumor proliferation, migration, and invasion
- (2018) Zhijian Zhou et al. Cancer Biomarkers
- miR-378 functions as an onco-miRNA by targeting the ST7L/Wnt/β-catenin pathway in cervical cancer
- (2017) Shengjie Li et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer
- (2016) Solange Peters et al. CANCER TREATMENT REVIEWS
- Communication by Extracellular Vesicles: Where We Are and Where We Need to Go
- (2016) Mercedes Tkach et al. CELL
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular histology of lung cancer: From targets to treatments
- (2015) Steven L. Wood et al. CANCER TREATMENT REVIEWS
- MiR-378 suppresses prostate cancer cell growth through downregulation of MAPK1 in vitro and in vivo
- (2015) Qi-guang Chen et al. TUMOR BIOLOGY
- Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
- (2014) Marina Colombo et al. Annual Review of Cell and Developmental Biology
- Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients
- (2014) Margaritis Avgeris et al. BIOLOGICAL CHEMISTRY
- MiR-378 is an independent prognostic factor and inhibits cell growth and invasion in colorectal cancer
- (2014) Guang-jun Zhang et al. BMC CANCER
- MiR-378 Promotes the Migration of Liver Cancer Cells by Down-Regulating Fus Expression
- (2014) Jichun Ma et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- MicroRNA-378 inhibits cell growth and enhancesl-OHP-induced apoptosis in human colorectal cancer
- (2014) Kai-Yu Wang et al. IUBMB LIFE
- Tumor-Associated Circulating MicroRNAs as Biomarkers of Cancer
- (2014) Jin Wang et al. MOLECULES
- Interplay Between Heme Oxygenase-1 and miR-378 Affects Non-Small Cell Lung Carcinoma Growth, Vascularization, and Metastasis
- (2013) Klaudia Skrzypek et al. ANTIOXIDANTS & REDOX SIGNALING
- Lung Cancer in China
- (2013) Jun She et al. CHEST
- MiR-378 Inhibits Progression of Human Gastric Cancer MGC-803 Cells by Targeting MAPK1 In Vitro
- (2013) Bojian Fei et al. ONCOLOGY RESEARCH
- Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor- 1
- (2011) M. J. Szczepanski et al. HAEMATOLOGICA
- Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma
- (2011) J. D. Arroyo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started